Nektar Initiates Phase 3 AD Program, But Execution and Dilution Risks Loom

What happened

Nektar Therapeutics announced the start of its Phase 3 ZENITH AD program for rezpegaldesleukin in moderate-to-severe atopic dermatitis, initiating two registrational trials (ZENITH AD-1 and AD-2) with a third to begin in September 2026. The program is based on Phase 2b data showing durable responses with monthly and quarterly maintenance dosing, including an up to five-fold increase in EASI-100 between weeks 16 and 52. However, the Phase 2b durability data came from a responder-enriched cohort, limiting direct comparability to incumbents like Dupixent until Phase 3 reports intent-to-treat results. The company still faces significant dilution risk from a planned $300 million equity offering, as it has no committed capital sources and burns ~$50 million per quarter. With topline data not expected until mid-2028 and a BLA submission targeted for 2029, near-term value hinges on financing terms and flawless trial execution rather than clinical results.

Implication

The Phase 3 initiation aligns with the master report's base case, removing one key uncertainty (Q2 2026 start) and supporting the WAIT rating's precondition for a potential upgrade. However, the stock still prices in a successful, non-dilutive financing outcome that remains uncertain; the announced $300M offering could still come at a discount or with heavy warrant coverage. Investors should monitor the final offering price and whether Phase 3 protocols remain consistent with FDA alignment (EASI-75 co-primary, 24 µg/kg Q2W induction). Additionally, the inclusion of a treatment-experienced cohort (ZENITH AD-3) introduces complexity that could dilute endpoint separation if not properly stratified. Until the financing closes at reasonable terms and the trials are fully enrolled with observable site activity, the risk/reward remains skewed to the downside. Long-term success depends on replicating Phase 2b durability in an ITT population and overcoming manufacturing comparability risks tied to CMO dependency.

Thesis delta

The Phase 3 start, while expected, removes a key downside risk (delayed initiation) and modestly supports the base case. However, the financing path remains the dominant near-term variable, and the inclusion of treatment-experienced patients in one study adds a new layer of execution risk. The thesis shifts from 'wait for Phase 3 start' to 'wait for favorable financing terms and protocol consistency' as the next catalyst.